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Reduction of the LVOT gradient post PTSMA was determined by echocardiographic. 
Results: All patients demonstrated regional myocardial hyperenhancement of the inter- 
ventricular septum, exclusively located on the right ventricular side of the septum in 7. In 
patients with exclusively right sided hyperenhancement, the LVOT gradient reduction 
was 3Oi 28 mmHg versus 78* 22 mmHg in the remaining patients (p<O.OOl). Myocardial 
injury size in the right sided group was significantly lower (lo+ 4 g vs. 23+ 8 g, pcO.001). 
In these patients the volume of ethanolinjected was lower (2.6* 1.2 ml versus 3.6* 1.8 
ml, p = 0.19) and the ethanol was infused distal of a bi- or trifurcation in 4 out of 7 
patients. In the remaining patients ethanol was injected proximally in the septal branch. 
Conclusion: In patients with HOCM, size and location of myocardial injury induced by 
PTSMA can be determined using contrast-enhanced MRI. An exclusively right sided 
locatlon of myocardial injury is associated with lesser reduction of the LVOT gradient. 
1014-86 Progressive Left Ventricular Impairment in 
Hypertrophic Cardiomyopathy Patients Is Determined 
by Functional Location of Mutation 
Saidi A. Mohiddin, Judy Wlnkler. Dorothy Tripodi, Dorothea McAreavey, Lameh 
Fananapazir, National Heart Lung and Blood Institute, Bethesda, MD 
Background: More than 70 mutations affecting emyosin heavy chain (P-MHC coded by 
MYH7j, the commonest cause of familial hypetitophic cardiomyopathy (FHC), are 
reported. Mutation-specific natural history contributes to patient management, but most 
mutations are uncharacterized. We sought to determine if the affected functional domain 
Influences outcome, allowing domain-specific prognosis. Several MYH7 mutations affect 
the converter (CD), whlch@nctions as a fulcrum for force leverage. Methods: Residues 
of the CD were predicted from FMHC’s 3-D structure. Echo and clinical date from unre- 
lated FHC patients with a CD mutation (CD+) were compared with 98 unrelated patients 
without CD mutations (CD-), a subset of whom had other MYH7mutations. Results: 
There were 9 CD mutations in 22 pattents. Compared to all CD- patients, CD+ patients 
were diagnosed with FHC at younger age (22210 vs 35il8 years, p<O.OOl) and more 
frequently had a family history of HCM (15/22 vs 42/98, ~~0.05). Magnitude of left ven- 
tricular (LV) hypertrophy and LV gradients were similar. CD+ patients had lower frac- 
tional shortening (FS; 36214 vs 42+7, pcO.005) despite a lower mean age (34214 vs 
47218 years, pcO.005). FS was ~30% in 7121 CD+ patients and only 4/83 CD- patients, 
pcO.001. CD+ patients with FS<30 were older than those with FS>30 (43+9 vs 30+14 
years, p<O.O5). MYH7mutations other than CD were found in 17/98 CD- patients; FHC 
was diagnosed at a younger age in CD+ patients (22tlO vs 31~17 years, p<O.O5), left 
atrial (LA) size was smaller (45&10 mm vs 54210; P=O.Ol) and FS lower (4227 vs. 4727, 
p=O.Ol) compared to patients with non-CD MYH7 mutations. Conclusions: Despite simi- 
lar magnitude of LV hypertrophy and LV obstruction. there are differences between FHC 
associated with CD mutations. non CD MYH7 mutations and non-MYH7causes. (1) CD 
mutations result in higher penetrance and presentation at a younger age; (2) CD muta- 
tlons are more likely to cause progressive LV systolic dysfunction; (3) LA distension 
associated with non CD MYH7 mutations may reflect greater diastolic dysfunction. Identi- 
fication of mutant functional domain will contribute to the management of FHC patients 
with MYH7 mutations of undetermined natural history. 
1014-87 Factors Associated With Increased Risk of Sudden 
Death in Young Patients With Hypertrophic 
Cardiomyopathy 
Dorothea McAreavey, Jeffrey P. Moak, Dorothy Tripodi. Saidi A. Mohiddin, Rose M. 
Wienhoff, Lameh Fananapazir, National Institutes of Health, Bethesda, MD, Washington, 
DC 
Background: Hypertrophic cardiomyopathy (HCM) I” the young is associated with 
increased risk for sudden death (SD). We determined outcomes in a cohort of children 
attending a tertiary referral center, and prognostic significance of the presenting clinical 
findings. METHODS: Study comprised of 260 children aged <20 years (mean, lOr6 
years) with HCM: 13 (5%) presented with cardiac arrest, 52 (20%) had syncope, 34 
(13%) had presyncope. 91 (35%) had chest pain, 84 (32%) had dyspnea, and 80(31%) 
were asymptomatic. Studies included echocardiography, Halter, treadmIll exercise test, 
exercise thallium scintigraphy, cardiac catheterization, and electrophysiology study 
(EPS). Results: 240 children, or 92%, had one or more risks for SD, Table. Therapy 
included implantable defibrillators (ICD) in 56, pacemakers in 97, cardiac surgery for 
obstructtve HCM in 22, and cardiac transplantation in 6 (3 died post-operatively). Thirty- 
five adverse events: 20 deaths (13 SD); 8 cardiac arrests; and 7 ICD therapies. The 5- 
year sun/ival rate was 92+2%,and the 5.year event-free rate was 87+2%. Conclusions: 
(1) Traditional risk factors are common in young patients who presented to a tertiary 
referral center, and therefore as a group, have a poor predictive value. (2) Despite this 
high prevalence of risk factors associated wtth increased risk for SD, therapy directed at 
relieving symptoms and correcting identified abnormalities was associated with a prog- 
nosis similar to that reported from non-tertiary centers. 
Risk factors assocmted wth poor prognosis 
Parameter Prevalence 
Cardiac arrest or syncope 65/260(25%) 
LV outflow obstruction (cardiac cath) 11 O/210 (52%) 
LV wall thickness 320 mm 132/260(51%) 
Non-sustained ventricular tachycardia VT during 24-48 hr Halter 431234 (18%) 
Myocardial ischemia by exercise thallium 135/175(77%) 
Abnormal BP response to exercise 741224 (33%) 
Family History of sudden death 72/230 (31%) 
Genetic mutation associated with poor prognosis 20/48 (42%) 
Sustained ventricular tachycardia induced at EPS 371139 (27%) 
1014-88 Progression of Hypertrophic Cardiomyopathy to Dilated 
Cardiomyopathy: Three New Mutations in Genes 
Encoding Sarcomeric Proteins With Two Cases of 
Double Heterozygosity 
Luisa Nanni Maurizio Pieroni, Barbara Slmionati, Rosanna Zimbello, Cristina Chlmentl, 
Getolamo Lanfranchi, Attilio Maseri, Andrea Frustaci, CRIBI Biotechnology Centre, 
Universita degll Studi di Padova, Padova, Italy, Univetsit& Cattolica del Sacro Cuore, 
Roma. Italy 
Background: About 10% of cases of hypertrophic cardiomyopathy (HCM) develop a 
dilated cardiomyopathy (DCM). The molecular mechanisms of this evolution are still 
unknown. The genes accounting for approximately 2/3 of all HCM cases are O-myosin 
heavy chain (MyH7), myosin-binding protein C (MyBPC) and cardiac troponin T (cTnT). 
In order to investigate if specific gene mutations are consistently associated with HCM 
progressing to DCM we have performed mutational analysis of these genes in 10 unre- 
lated affected patients (pts). 
Methods: We enrolled 10 unrelated pts with HCM who progressed to DCM. symptomatic 
and with left ventricular dilatation and impaired contractile function but no ouflow tract 
gradient. Mutational analysis was performed for the entire coding region and exon-intron 
boundaries of the MyH7, MyBPC and cTnT genes using direct sequencing. 
Results: In these 3 genes a total of 5 missense mutations were found in 5 pts; 2 of these 
were previously described mutations and 3 were new mutations. The already known 
mutations were a MyH7 mutation (R453C) affecting the actin binding property and a vari- 
ation in the cTnT gene (K236R). The first new MyH7 mutation (L517M) occurred in the 
head-rod junction of myosin, lying close to a reactive cyst&e (Cys-695). The second 
MyH7 mutation (Q734E) occurred in the light chain-binding site following the reactive 
cysteines. A new MyBPC mutation (S236G) was found in the IG-kke C2-type domain 1 of 
the protein and is likely to disrupt the phosphorylation site. The simultaneous presence of 
two missense mutations in two different genes was observed in two pts, one carrying the 
newly discovered MyH7 (L517M) and MyBPC mutations and one carrying the MyBPC 
and the cTnT mutations. 
Conclusion: We identified 3 formerly unreported mutations and the simultaneous pres- 
ence of mutations I” two different genes in 2 pts. However we failed to identify a specific 
mutation in our pts with HCM who progressed to DCM. Thus the actlon of multiple gene 
mutations, the presence of modifier genes and post-transcriptional mechanisms appear 
to play a major role in the progression from HCM to DCM. 
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1038-68 Left Ventricular Systolic Function and Survival in a 
Contemporary Cohort of Patients With Heart Failure 
Frederick A. Masoudi, Pam wore, Saif S. Rathore. Joanne M. Foody, Diana L. Ordin, 
Harlan M. Krumholz. Edward P. Havranek. Denver Health Medical Center, Denver, CO, 
Colorado Foundation for Medical Care, Aurora, CO 
Background: Although preserved left ventricular systolic function (LVSF) reportedly con- 
fers a better prognosis than impaired LVSF in patients with heart failure, it is unclear if 
this pattern exists in current practice. Our goal was to describe the independent relation- 
ship between LVSF and survival in a cohort of patients with heart failure. 
Methods: We used data from the CMS-sponsored National Heart Failure (NHF) Project, 
a national sample of Medicare beneficiaries hospitalized with a principal diagnosis of 
heart failure in 1998 and 1999. We studied patients at least 65 years old who were dis- 
charged alive (n=31,991). Multivariable Cox proportional hazards regression with mean 
follow-up of one year was employed, adjusting for patlent factors and differences in ACE- 
inhibitor prescription at discharge. 
Results: Crude mortality rates and fully adjusted hazard ratios for mortality among ACE- 
treated and non-ACE-treated patients are presented below. In the multivariable model, 
there was a graded inverse relationship between LVSF and mortality. Although ACE- 
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inhibitors were associated with increased survival regardless of LVSF. the relationship 
was lees pronounced in patients with preserved LVSF (p<O.Ol). 
Conclusions: Although older patients hospitalized with heart failure and normal LVSF 
have belter survival than those with impaired LVSF, mortality rates are high in all groups. 
ACE-inhibitors attenuate the relationship between reduced LVSF and Increased morial- 
ity. 
Normal Mild Moderate Severe LVSF not 
” 
Crude 1 -year 
mortality 
Adjusted HA 
(95% Cl) 
(--) ACE-treated 
Adjusted HR 
(95% Cl) 
(c) ACE-treated 
1038-89 
LVSF LVSD LVSD LVSD documented 
7,140 2,875 4,115 5,846 12,015 
27% 31% 34% 41% 41% 
1.00 1.22 1.30 1.65 1.37 
(1.10, (1.18, 1.44) (1.50, (1.28, 1.47) 
1.36) 1.80) 
1 .oo 1.07 1.20 1.45 1.30 
(0.95, (1.08.1.33) (1.32,1.59 (1.21, 1.43) 
1.21) ) 
Lefi Atrial Volume Is More Strongly Associated With 
Prevalent Congestive Heart Failure and Predictive of 
Incident Congestive Heart Failure in the Elderly Than 
Doppler Mitral Inflow Velocities or Deceleration Time 
John S. Gotrdiener. Dalane W. Kitzman, Gerard P. Aurigemma, Alice M. Arnold, Cheryl 
S. Egher, Karen M. Fowle, Jeffrey C. Hill, St. Francis Hospital, Roslyn, NY, NHLBI, 
Bethesda, MD 
In elderly pts, diastolic dysfunction presumably accounts for the large proportion (approx. 
50% of our cohort) of heart failure (HF) with normal systolic function (diastolic HF). Both 
LA size and Doppler parameters of L V diastolic filling are commonly abnormal in HF.We 
evaluated the relative contribution of LA volume (vol)(ZD echo ellipsoid model), mitral 
inflow deceleration (DECEL) time, early (Epk)and late (Apk) peak velocities of mitral 
inflow, as well as LV ejection fraction (EF) for association with prevalent HF and for pre- 
diction of incident HF. Methods: Within the Cardiovascular Health Study. a community- 
based study of cardiac risk in individuals > age 85, we did a case control study of 636 
participants (ppts) (av age 79+/-6 yrs, range 68-99) of whom 121 had HF (prevalent HF) 
at the time of echo evaluation, 179 developed HP within 5 yrs of the baseline echo (inci- 
dent HF), and 336 were age and gender matched controls. Odds ratios were calculated 
in a multivariate model adjusting for age, sex, prevalent and subclinical CV disease, dia- 
betes, hypeltension, height, weight, and atrial fibrillation. Results: see table. Conclusion: 
LAvol is associated with prevalent CHF and is predictive of incident CHF independently 
of LV systolic function, and independently of mitral inflow velocities, deceleration time, as 
well as clinical covariates. While Apk velocity has associative and predictive value, Epk 
and DECEL time do not. 
Odds Ratios (95% C.I.) 
CHF LAvol Decel time E velocity A velocity &F 
Prevalent 3.7(2.3-6.0)’ .9(.6-1.4) 1.1(.7-1.7) 1.5(1 .O-2.3) 7(3-l 6) 
* 
Incident 2.7(1.9-3.8) 1.1(.9-1.4) l.l(.E-1.4) 1.3(1.0-l .8) 2.4(1.2-4.8) 
$ $ 
‘p,<.OOl ,$pc.O4. Odds ratios per parameter S.D. except for EF which was expressed 
as a categorical variable -decreased vs normal. 
1038-70 Diastolic Dysfunction: An Important Predictor of 
Survival in Patients With Preserved Systolic Function 
Richard V. Milani. Carl J. Lavie, Mandeep R. Mehra, Josh Kurtz, Hector 0. Ventura, 
Ochsner Clinic Foundation, New Orleans, LA 
Background: Diastolic dysfunction (DD) carries a poor prognosis when identified in 
patients (pts) with reduced systolic function (SF). However, little is known regarding out- 
come in pts with diastolic filling abnormalities and preserved SF. 
Methods: We assessed diastolic filling and mortality in 7,216 pts (2,885 pts < 50 years, 
2,536 pts 50-70 years, and 1,795 pts > 70 years) with preserved SF (EF >/= 50%) 
referred for echo (mean follow-up of 3.1 years). DD was categorized as either relaxation 
abnormality, pseudonormalization, or restrictive filling panem by standard Doppler 
echocardiographic criteria. 
ResuI1s: DD was extremely prevalent in all age groups, occurring in 40%, 44%. and 70% 
of pts under age 50, 50-70, and > 70 years, respectively. Although EF and BMI were sim- 
tlar in pts with and without DD for all age groups. marked increases in mortality were 
observed in pts with DD (2.fold increased mortality I” pts < 70 years, and 38% increased 
mortality in pts > 70 years; see figure). All categories of DD had similar increases in rnor- 
tality. 
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Conclusions: DD is highly prevalent in pts with preserved SF, increases with age, and is 
associated with a marked increase in mortality. 
1038-71 Heart Failure and/or Left Ventricular Systolic 
Dysfunction Complicating Myocardial Infarction Is 
Common and Accounts for the Majority of In-Hospital 
Myocardial Infarction Mortality: Results of the VALIANT 
Registry 
Eric J. Velazauez. W. Douglas Weaver, Paul W. Armstrong, Rakhi Kilaru, Rafael Diaz. 
Harvey D. White, Wiek H. van Gilst, Jiri Spat, Christopher M. O’Connor, Gary S. Francis, 
Helmut Drexler, Viatcheslav Y. Mareev, Aldo P. Maggioni, Jeffrey D. Leimberger, Marlin 
Myers, Marc Henis, Robert M. Califf, Duke Clinical Research Institute, Durham, NC 
Background: We designed a registry as an adjunct to the VALsartan In Acute myocar- 
dial iNfarcTion (VALIANT) trial to define the incidence of heart failure (HF) and/or left 
ventricular systolic dysfunction (LVSD) prior to discharge following myocardial infarction 
(MI) and lo determine its incremental mortality risk. 
Methods/Results: The VALIANT registry enrolled 5,592 consecutive Ml pts (85 hospi- 
tals. 9 countries) from 200&2001 during prearranged screening periods, with follow-up 
until in-hospital death or discharge. Overall in-hospital modality was 6.8%. Of the MI pts 
entered in cur registry. 42% (n = 2,352) had HF and/or LVSD defined by either clinical or 
radiographic signs of HF and/or LVSD imaging evidence. Selected outcome differences 
are presented (Table). A multivariable logistic model for in-hospital mortality was devel- 
oped (global x 2 = 479.29; C-Index = 0.811). Adjusting for baseline risk, HF and/or LVSD 
was associated with a hazard ratio of 4 39 (95% Cl 3.33 - 5.84). Among HF and/or LVSD 
pts, 34.2% received angiotensin-converting enzyme (ACE) inhibitors and 58.0% beta 
blockers within 24 hours after presentation; 31.4% underwent percutaneous and 11 .O% 
surgical revascularization before discharge. 
Conclusions HF and/or LVSD cccurs in a sizeable minority of contemporary Ml pts and 
accounts for the vast majority of deaths. ldentlfying these pts during the ccurse of Ml 
could trigger mere intensive medical therapy. including revascularization, than that 
observed in the registry. 
Outcomes by In-Hospital HF and/or LVSD Development 
Atrial fibrillation. % 
Stroke. % 
Recurrent MI, % 
Mortality, % 
Mean length of stay, 
days 
HF and/or LVSD (n = No HF and/or LVSD (n = 
2,352) 3,240) 
16.3 7.1 
2.2 0.9 
2.5 1.4 
12.9 2.2 (p < 0.001) 
12.0 7.6 
1038-72 Are NT-Pro Brain Natriuretic Peptides Related to 
Systolic and Diastolic Left Ventricular Function at 
Baseline and During Antihypertensive Treatment? The 
LIFE Study 
Kristian Wachtell. Michael H. Olsen, Christian Tuxen. Lia E. Bang, Christian Hall, Per R. 
Hildebrandt. Hans Ibsen. Jens E. Rokkedal, Richard 6. Devereux, Glostrup University 
Hospital, Glostrup, Denmark, The Weill Medical College of Cornell University, New York, 
NY 
Background: NT-pro-brain natriuretic peptide (NT-pro-BNP) has been shown to predict 
systolic left ventricular (LV) function in patients with congestive heart failure (CHF). Fur- 
thermore, LV function is related lo LV mass and wall stress. It remains unclear whether 
NT-pro-BNP IS related to systolic or diastolic LV function in hypertensive patients without 
CHF and whether this relation is independent of wall stress and LV mass. 
Methods: Clinical, laboratory and echocardiographic variables were assessed in 184 
hypertensive patients with ECG LV hypertrophy. aged 55-80 (mean 66*7 years) at base- 
line after 2 weeks’ placebo and after one year of systematic antihypertensive treatment. 
NT-pro-BNP was measured by immunoassay (Elecsys proBNP). 
Results: NT-pro-BNP at baseline was negatively related to endocardial (EFS. r=-0.251) 
and midwall fractional shortening (MWS, r=-0.245. both p=O.OOl). With adjustment for 
circumferential end-systolic stress, MWS (p=-0.155, ~~0.05) but not EFS (@=-0.028, NS) 
remained related to NT-pro-BNP. However, when taking LV mass wall stress into 
account there was only a trend towards a relation between NT-pro-BNP and MWS (p=- 
